Ligand Pharma Inc Roche Contingent Value Rights (LGNDZ)

[surf1944]

8:30AM Ligand announces positive preclinical data for Glucagon Program in Model of Type 1 Diabetes (LGND) 34.80 : Co announced the presentation of a poster titled "Glucagon Receptor Antagonist LGD-6972 Is Efficacious in Streptozotocin-Induced Diabetic Mice" at the 73rd Scientific Sessions of the American Diabetes Association in Chicago. The poster provides data from preclinical studies of Ligand's novel compound, LGD-6972, demonstrating significant glucose lowering activity in an animal model of type 1 diabetes.

Highlights of the presentation include:

LGD-6972 is a potent and selective antagonist of the glucagon receptor (GCGR) that has previously demonstrated activity in pre-clinical models of type 2 diabetes
LGD-6972 significantly lowered fasting and non-fasting glucose levels in a mouse model of type 1 diabetes
LGD-6972 reduced HbA1c, ketone bodies, and free fatty acids in diabetic mice
LGD-6972 had additive effects when used in combination with insulin therapy and may be useful in an insulin sparing regimen